Skip to main content
SpringerLink
Log in

Post-Traumatic Stress Disorder

Pathophysiological Aspects and Pharmacological Approaches to Treatment

  • Disease Management
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Post-traumatic stress disorder (PTSD) is a syndrome of psychophysiological sequelae occurring in the aftermath of severe emotional trauma. Phenomenologically, symptoms occur in 3 clusters: re-experiencing, avoidance and hyperarousal. Other psychiatric disorders such as depression, panic disorder and substance abuse frequently co-occur with PTSD.

Treatment strategies for PTSD are often multimodal and attempt to integrate biological, behavioural, cognitive, psychodynamic and social formulations. Pharmacotherapy must target specific symptoms in all 3 clusters, and address the presence of comorbid psychiatric disorders. Psychotropic medication can facilitate psychotherapeutic work, or serve as the primary modality in a biologically based approach to treatment.

Specific medications used in the treatment of PTSD span a broad spectrum of pharmacological agents. The most empirically studied agents, tricyclic antidepressants and monoamine oxidase inhibitors, demonstrate a definite but limited impact on specific PTSD symptoms. For the patient who presents in an acute symptomatic state, benzodiazepine anxiolytics may be appropriate. For longer term treatment, selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), particularly fluoxetine, appear to have broader spectrum therapeutic effects on specific PTSD symptom clusters. Both antidepressants and anxiolytics have, in some studies, shown beneficial effects on depressive symptoms and anxiety, without measurable impact on the symptoms more specific to PTSD.

Maintenance pharmacotherapy frequently requires a multidrug regimen; an SSRI may serve as the primary agent, with adjunctive agents targeting residual hyperarousal and re-experiencing symptoms. Benzodiazepines, sedating tricyclic or antihistamine compounds, and the noradrenergic drugs Clonidine and propranolol are used in this way. Buspirone, a serotonergic anxiolytic, may serve a similar role for some patients, and cyproheptadine in particular appears to be helpful for nightmares. The antikindling agents carbamazepine and valproic acid (sodium valproate) have also been reported to be beneficial, and may provide an alternative for patients with persistent hyper-reactivity and explosiveness that have not responded to other treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shay J. Achilles in Vietnam. New York: Atheneum, 1994

    Google Scholar 

  2. Gersons BPR, Carlier IVE. Post-traumatic stress disorder: the history of a recent concept. Br J Psychiatry 1992; 161: 742–8

    PubMed  CAS  Google Scholar 

  3. Davidson JRT, Foa EB, editors. Posttraumatic stress disorder: DSM IV and beyond. Washington, DC: American Psychiatric Press, 1993: ix–xiii

    Google Scholar 

  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatrie Association, 1980

    Google Scholar 

  5. American Psychiatrie Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatrie Association, 1987

    Google Scholar 

  6. American Psychiatrie Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatrie Association, 1994

    Google Scholar 

  7. Breslau N, Davis GC, Andreski P. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 1991; 48: 216–22

    PubMed  CAS  Google Scholar 

  8. Davidson JRT, Fairbank JA. The epidemiology of post-traumatic stress disorder. In: Davidson JRT, Foa EB, editors. Posttraumatic stress disorder: DSM IV and beyond. Washington, DC: American Psychiatrie Press, 1993: 147–69

    Google Scholar 

  9. Rothbaum BO, Foa EB. Subtypes of posttraumatic stress disorder and duration of symptoms. In: Davidson JRT, Foa EB, editors. Posttraumatic stress disorder: DSM IV and beyond. Washington, DC: American Psychiatrie Press, 1993: 23–35

    Google Scholar 

  10. Blank Jr AS. The longitudinal course of posttraumatic stress disorder. In: Davidson JRT, Foa EB, editors. Posttraumatic stress disorder: DSM IV and beyond. Washington, DC: American Psychiatrie Press, 1993: 3–22

    Google Scholar 

  11. Shalev AY, Bonne O, Eth S. Treatment of posttraumatic stress disorder: a review. Psychosom Med 1996; 58: 165–82

    PubMed  CAS  Google Scholar 

  12. Giller Jr EL. Pharmacotherapy of PTSD. In: Miller DJ, editor. Handbook of post-traumatic stress disorders. New York: Plenum Publishing Co. In press

  13. Friedman MJ, Yehuda R. Post-traumatic stress disorder and comorbidity: psychobiological approaches to differential diagnosis. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 429–45

    Google Scholar 

  14. Sargant WW, Slater E. Acute war neuroses. Lancet 1940; 140: 1–2

    Google Scholar 

  15. Davidson J. Drug therapy of post-traumatic stress disorder. Br J Psychiatry 1992; 160: 309–14

    PubMed  CAS  Google Scholar 

  16. Sargant WW, Slater E. The use of drugs in psychotherapy. In: Sargant WW, Slater E, editors. An introduction to physical methods of treatment in psychiatry. New York: Science House, 1972: 142–62

    Google Scholar 

  17. van der Kolk BA. The drug treatment of post-traumatic stress disorder. J Affect Dis 1987; 13: 203–13

    PubMed  Google Scholar 

  18. Solomon SD, Gerrity ET, Muff AM. Efficacy of treatments for posttraumatic stress disorder: an empirical review. JAMA 1992; 268: 633–8

    PubMed  CAS  Google Scholar 

  19. Grinker RR, Spiegel JJ. Men under stress. New York: McGraw-Hill, 1945

    Google Scholar 

  20. Kardiner A. The traumatic neuroses of war. New York: P Hoeber, 1941

    Google Scholar 

  21. Bremner JD, Krystal JH, Southwick SM, et al. Functional neuroanatomical correlates of the effects of stress on memory. J Trauma Stress 1995; 8: 527–53

    PubMed  CAS  Google Scholar 

  22. Charney DS, Deutch AY, Krystal JH, et al. Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50: 294–305

    CAS  Google Scholar 

  23. Friedman MJ. Interrelationships between biological mechanisms and pharmacotherapy of posttraumatic stress disorder. In: Wolf ME, Mosnaim AD, editors. Posttraumatic stress disorder: etiology, phenomenology, and treatment. Washington, DC: American Psychiatric Press Inc., 1990: 204–25

    Google Scholar 

  24. Friedman MJ. Biological approaches to the diagnosis and treatment of post-traumatic stress disorder. J Trauma Stress 1991; 4: 67–91

    Google Scholar 

  25. Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995

    Google Scholar 

  26. Giller Jr EL, editor. Biological assessment and treatment of posttraumatic stress disorder. Washington, DC: American Psychiatric Press Inc., 1990

    Google Scholar 

  27. Kolb LC. A neuropsychological hypothesis explaining posttraumatic stress disorders. Am J Psychiatry 1987; 144: 989–95

    PubMed  CAS  Google Scholar 

  28. Krystal JH, Kosten TR, Southwick S, et al. Neurobiological aspects of PTSD: review of clinical and preclinical studies. Behav Ther 1989; 20: 177–98

    Google Scholar 

  29. Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatric Press Inc., 1994

    Google Scholar 

  30. Pitman RK. Biological findings in posttraumatic stress disorder: implications for DSM-IV classification. In: Davidson JRT, Foa EB, editors. Posttraumatic stress disorder: DSM-IV and beyond. Washington, DC: American Psychiatrie Press Inc., 1993

    Google Scholar 

  31. Shalev A. Post-traumatic stress disorder: a biopsychological perspective. Isr J Psychiatry Relat Sci 1993; 30: 102–9

    PubMed  CAS  Google Scholar 

  32. Southwick SM, Bremner D, Krystal JH, et al. Psychobiologic research in post-traumatic stress disorder. Psychiatr Clin North Am 1994; 17: 251–64

    PubMed  CAS  Google Scholar 

  33. van der Kolk B, Greenberg M, Boyd H, et al. Inescapable shock, neurotransmitters, and addiction to trauma: toward a psychobiology of post traumatic stress. Biol Psychiatry 1985; 20: 314–25

    PubMed  Google Scholar 

  34. van der Kolk BA. Psychological trauma. Washington, DC: American Psychiatrie Press Inc., 1987

    Google Scholar 

  35. van der Kolk BA, Saporta J. The biological response to psychic trauma: mechanisms and treatment of intrusion and numbing. Anxiety Res 1991; 4: 199–212

    Google Scholar 

  36. Yehuda R, Giller EL, Southwick SM, et al. Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry 1991; 30: 1031–48

    PubMed  CAS  Google Scholar 

  37. Yehuda R, Resnick H, Boaz K, et al. Long-lasting hormonal alterations to extreme stress in humans: normative or maladaptive? Psychosom Med 1993; 55: 287–97

    PubMed  CAS  Google Scholar 

  38. Blanchard EB, Kolb LC, Pallmeyer TP, et al. Psychophysiological study of posttraumatic stress disorder in Vietnam veterans. Psychiatr Q 1982; 54: 220–9

    PubMed  CAS  Google Scholar 

  39. Blanchard EB, Kolb LC, Gerardi RJ, et al. Cardiac response to relevant stimuli as an adjunctive tool for diagnosing posttraumatic stress disorder in Vietnam veterans. Behav Ther 1986; 17: 592–606

    Google Scholar 

  40. Blanchard EB, Kolb LC, Prins A, et al. Psychophysiological responses in the diagnosis of posttraumatic stress disorder in Vietnam veterans. J Nerv Ment Dis 1991; 179: 371–3

    PubMed  CAS  Google Scholar 

  41. Gerardi RJ, Blanchard EB, Kolb LC. Ability of Vietnam veterans to dissimulate a psychophysiological assessment for post-traumatic stress disorder. Behav Ther 1989; 20: 229–43

    Google Scholar 

  42. Malloy PF, Fairbank JA, Keane TM. Validation of a multimethod assessment of post-traumatic stress disorders in Vietnam veterans. J Consult Clin Psychol 1983; 51: 488–94

    PubMed  CAS  Google Scholar 

  43. Pallmeyer TP, Blanchard EB, Kolb LC. The psychophysiology of combat-induced post-traumatic stress disorder in Vietnam veterans. Behav Res Ther 1986; 24: 645–52

    PubMed  CAS  Google Scholar 

  44. Pitman RK, Orr SP, Forgue DF, et al. Psychophysiologic assessment of post-traumatic stress disorder imagery in Vietnam combat veterans. Arch Gen Psychiatry 1987; 44: 970–5

    PubMed  CAS  Google Scholar 

  45. Pitman RK, Orr SP, Forgue DF, et al. Psychophysiologic response to combat imagery of Vietnam veterans with posttraumatic stress disorder versus other anxiety disorders. J Abnorm Psychol 1990; 99: 49–54

    PubMed  CAS  Google Scholar 

  46. McFall ME, Murburg MM. Psychophysiological studies of combat-related PTSD: an integrative review. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatrie Press Inc., 1994: 161–74

    Google Scholar 

  47. Murburg MM, McFall ME, Veith RC. Basal sympathoadrenal function in patients with PTSD and depression. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatrie Press Inc., 1994: 175–88

    Google Scholar 

  48. McFall ME, Murburg MM, Roszell DK, et al. Psychophysiologic and neuroendocrine findings in posttraumatic stress disorder: a review of theory and research. J Anxiety Dis 1989; 3: 243–57

    Google Scholar 

  49. McFall ME, Veith RC, Murburg MM. Basal sympathoadrenal function in posttraumatic stress disorder. Biol Psychiatry 1992; 31: 1050–6

    PubMed  CAS  Google Scholar 

  50. Boudewyns PA, Hyer L. Physiological response to combat memories and preliminary treatment outcome in Vietnam veteran PTSD patients treated with direct therapeutic exposure. Behav Ther 1990; 21: 63–87

    Google Scholar 

  51. Dobbs D, Wilson WP. Observations on persistence of war neurosis. Dis Nerv Syst 1960; 21: 686–91

    PubMed  CAS  Google Scholar 

  52. McFall ME, Murburg MM, Ko GN, et al. Autonomie responses to stress in Vietnam combat veterans with posttraumatic stress disorder. Biol Psychiatry 1990; 27: 1165–75

    PubMed  CAS  Google Scholar 

  53. Attias J, Bleich A, Furman V, et al. Event-related potentials in post-traumatic stress disorder of combat origin. Biol Psychiatry 1996; 40: 373–81

    PubMed  CAS  Google Scholar 

  54. Butler RW, Braff DL, Rausch JL, et al. Physiological evidence of exaggerated startle response in a subgroup of Vietnam veterans with combat-related PTSD. Am J Psychiatry 1990; 147: 1309–12

    Google Scholar 

  55. Ross RJ, Ball WA, Cohen ME, et al. Habituation of the startle reflex in posttraumatic stress disorder. J Neuropsychiatry Clin Neurosci 1989; 1: 305–7

    PubMed  CAS  Google Scholar 

  56. Shalev AY, Orr SP, Peri T, et al. Physiologie responses to loud tones in Israeli patients with posttraumatic stress disorder. Arch Gen Psychiatry 1992; 49: 870–5

    PubMed  CAS  Google Scholar 

  57. Morgan III CA, Grillon C, Southwick SM, et al. Fear-potentiated startle in posttraumatic stress disorder. Biol Psychiatry 1995; 38: 378–85

    PubMed  Google Scholar 

  58. McFarlane A, Weber D, Clark C. Abnormal stimulus processing in posttraumatic stress disorder. Biol Psychiatry 1993; 34: 311–20

    PubMed  CAS  Google Scholar 

  59. Paige SR, Reid GM, Allen MG, et al. Psychophysiological correlates of posttraumatic stress disorder in Vietnam veterans. Biol Psychiatry 1990; 27: 419–30

    PubMed  CAS  Google Scholar 

  60. Pitman RK, van der Kolk BA, Orr SP, et al. Nalaxone-reversible analgesic response to combat-related stimuli in post traumatic stress disorder. Arch Gen Psychiatry 1990; 47: 541–4

    PubMed  CAS  Google Scholar 

  61. Orr SP, Claiborn JM, Altman B, et al. Psychometric profile of PTSD, anxious and healthy Vietnam veterans: correlations with psychophysiological response. J Consult Clin Psychol 1990; 58: 329–35

    PubMed  CAS  Google Scholar 

  62. Ross RJ, Ball WA, Sullivan KA, et al. Sleep disturbance as the hallmark of posttraumatic stress disorder. Am J Psychiatry 1989; 146: 697–707

    PubMed  CAS  Google Scholar 

  63. Dow BM, Kelsoe Jr JR, Gillin JC. Sleep and dreams in Vietnam PTSD and depression. Biol Psychiatry 1996; 39: 42–50

    PubMed  CAS  Google Scholar 

  64. Kosten TR, Mason JW, Giller Jr EL, et al. Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. Psychoneuroendocrinology 1987; 12: 13–20

    PubMed  CAS  Google Scholar 

  65. Mason JW, Giller Jr EL, Kosten TR, et al. Psychoendocrine approaches to the diagnosis and pathogenesis of posttraumatic stress disorder. In: Giller Jr EL, editor. Biological assessment and treatment of posttraumatic stress disorder. Washington, DC: American Psychiatric Press Inc., 1990: 65–86

    Google Scholar 

  66. Mason JW, Giller EL, Kosten TR, et al. Elevation of urinary norepinephrine/cortisol ratio in posttraumatic stress disorder. J Nerv Ment Dis 1988; 176: 498–502

    PubMed  CAS  Google Scholar 

  67. Yehuda R, Southwick S, Giller EL, et al. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 1992; 180: 321–5

    PubMed  CAS  Google Scholar 

  68. Yehuda R, Giller Jr EL, Southwick SM, et al. Relationship between catecholamine excretion and PTSD symptoms in Vietnam combat veterans and Holocaust survivors. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatric Press Inc., 1994: 203–19

    Google Scholar 

  69. Pitman R, Orr S. Twenty-four hour urinary Cortisol and catecholamine excretion in combat-related post-traumatic stress disorder. Biol Psychiatry 1990; 27: 245–7

    PubMed  CAS  Google Scholar 

  70. Blanchard EB, Kolb LC, Prins A, et al. Changes in plasma norepinephrine to combat-related stimuli among Vietnam veterans with post traumatic stress disorder. J Nerv Ment Dis 1991; 179: 371–3

    PubMed  CAS  Google Scholar 

  71. Murburg MM, McFall ME, Ko GN, et al. Stress-induced alterations in plasma catecholamines and sympathetic nervous system function in PTSD. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatrie Press Inc., 1994: 189–202

    Google Scholar 

  72. Murburg MM, McFall ME, Lewis N, et al. Plasma norepinephrine kinetics in patients with posttraumatic stress disorder. Biol Psychiatry 1995; 38: 819–25

    PubMed  CAS  Google Scholar 

  73. Hamner MB, Diamond BI. Elevated plasma dopamine in posttraumatic stress disorder: a preliminary report. Biol Psychiatry 1993; 33: 304–6

    PubMed  CAS  Google Scholar 

  74. Perry BD, Giller EL, Southwick SM. Altered platelet alpha-2-adrenergic binding sites in posttraumatic stress disorder. Am J Psychiatry 1987; 144: 1511–2

    PubMed  CAS  Google Scholar 

  75. Perry BD. Neurobiological sequelae of childhood trauma: PTSD in children. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatrie Press Inc., 1994: 233–55

    Google Scholar 

  76. Lerer B, Ebstein RP, Shestatsky M, et al. Cyclic AMP signal transduction in posttraumatic stress disorder. Am J Psychiatry 1987; 144: 1324–7

    PubMed  CAS  Google Scholar 

  77. Lerer B, Bleich A, Bennett ER, et al. Platelet adenylate cyclase and phospholipase C activity in posttraumatic stress disorder. Biol Psychiatry 1990; 27: 735–40

    PubMed  CAS  Google Scholar 

  78. Lerer B, Bleich A, Solomon Z, et al. Platelet adenylate cyclase activity as a possible biologie marker for posttraumatic stress disorder. In: Wolf ME, Mosnaim AD, editors. Posttraumatic stress disorder: etiology, phenomenology, and treatment. Washington, DC: American Psychiatrie Press Inc., 1990: 148–56

    Google Scholar 

  79. Kohn Y, Newman ME, Lerer B, et al. Absence of reduced platelet adenylate cyclase activity in Vietnam veterans with PTSD. Biol Psychiatry 1995; 37: 205–8

    PubMed  CAS  Google Scholar 

  80. Haier RJ, Buchsbaum MS, Murphy DL, et al. Psychiatrie vulnerability, monoamine oxidase, and the average evoked potential. Arch Gen Psychiatry 1980; 37: 340–5

    PubMed  CAS  Google Scholar 

  81. Wyatt RJ, Murphy DL, Belmaker RH, et al. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science 1973; 197: 916–8

    Google Scholar 

  82. Buchsbaum MS, Coursey RD, Murphy DL. The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science 1976; 194: 339–41

    PubMed  CAS  Google Scholar 

  83. Davidson J, Lipper S, Kilts CD, et al. Platelet MAO activity in posttraumatic stress disorder. Am J Psychiatry 1985; 142: 1341–3

    PubMed  CAS  Google Scholar 

  84. Southwick SM, Krystal JH, Morgan CA, et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50: 266–74

    PubMed  CAS  Google Scholar 

  85. Charney DS, Deutch AY, Southwick SM, et al. Neural circuits and mechanisms of post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 271–87

    Google Scholar 

  86. Bourne PB, Rose RM, Mason JW. Urinary 17-OHCS levels: data on seven helicopter medics in combat. Arch Gen Psychiatry 1967; 17: 104–10

    PubMed  CAS  Google Scholar 

  87. Bourne PB, Rose RM, Mason JW. 17-OHCS levels in combat: special forces ‘A’ team under threat of attack. Arch Gen Psychiatry 1968; 19: 135–40

    PubMed  CAS  Google Scholar 

  88. Rose RM, Poe RO, Mason JW. Psychological state and body size as determinants of 17-OHCS excretion. Arch Intern Med 1968; 121: 406–13

    PubMed  CAS  Google Scholar 

  89. Mason JW, Giller EL, Kosten TR, et al. Urinary-free Cortisol levels in post-traumatic stress disorder patients. J Nerv Ment Dis 1986; 174: 145–59

    PubMed  CAS  Google Scholar 

  90. Yehuda R, Boisoneau D, Mason JW, et al. Relationship between lymphocyte glucocorticoid receptor number and urinary-free Cortisol excretion in mood, anxiety and psychotic disorder. Biol Psychiatry 1993; 34: 18–25

    PubMed  CAS  Google Scholar 

  91. Yehuda R, Southwick SM, Nussbaum G, et al. Low urinary Cortisol excretion in PTSD. J Nerv Ment Dis 1991; 178: 366–9

    Google Scholar 

  92. Yehuda R, Kahana B, Binder-Brynes K, et al. Low urinary Cortisol excretion in Holocaust survivors with posttraumatic stress disorder. Am J Psychiatry 1995; 152: 982–6

    PubMed  CAS  Google Scholar 

  93. Yehuda R, Lowy MT, Southwick SM, et al. Lymphocyte glucocorticoid receptor number in post traumatic stress disorder. Am J Psychiatry 1991; 148: 499–504

    PubMed  CAS  Google Scholar 

  94. Yehuda R, Giller Jr EL, Levengood RA, et al. Hypothalamicpituitary-adrenal functioning in post-traumatic stress disorder: expanding the concept of the stress response spectrum. In: Friedman MJ, Charney DS, Deutch AY, editors. Neuro-biological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 351–65

    Google Scholar 

  95. Kudler H, Davidson J, Meador K, et al. The DST and posttraumatic stress disorder. Am J Psychiatry 1987; 144: 1068–71

    PubMed  CAS  Google Scholar 

  96. Olivera AA, Fero D. Affective disorders, DST, and treatment in PTSD patients: clinical observations. J Trauma Stress 1990; 3: 407–14

    Google Scholar 

  97. Halbreich U, Olympia J, Carson S, et al. Hypothalamo-pituitary-adrenal activity in endogenously depressed post-traumatic stress disorder patients. Psychoneuroendocrinology 1989; 14: 365–70

    PubMed  CAS  Google Scholar 

  98. Kosten TR, Wahby V, Giller Jr E, et al. The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder. Biol Psychiatry 1990; 28: 657–64

    PubMed  CAS  Google Scholar 

  99. Yehuda R, Southwick SM, Krystal JH, et al. Enhanced suppression of Cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry 1993; 150: 83–6

    PubMed  CAS  Google Scholar 

  100. Yehuda R, Teicher MH, Trestman RL, et al. Cortisol regulation in posttraumatic stress disorder: a chronobiological analysis. Biol Psychiatry 1996; 40: 79–88

    PubMed  CAS  Google Scholar 

  101. Segal M. Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. J Physiol 1979; 286: 401–15

    PubMed  CAS  Google Scholar 

  102. Gonzalez-Heydrich J, Peroutka SJ. Serotonin receptor and reuptake sites: pharmacologic significance. J Clin Psychiatry 1990; 51(4 Suppl.): 5–12

    PubMed  Google Scholar 

  103. Kahn RS, Van Praag HM, Wetzler S, et al. Serotonin and anxiety revisited. Biol Psychiatry 1988; 23: 189–208

    PubMed  CAS  Google Scholar 

  104. Coplan JD, Gorman JM, Klein DF. Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology 1992; 6: 189–200

    PubMed  CAS  Google Scholar 

  105. Risch SC, Nemeroff CB. Neurochemical alterations in serotonergic neuronal systems in depression. J Clin Psychiatry 1992; 53(10 Suppl.): 3–7

    PubMed  Google Scholar 

  106. Sandler M, Coppen A, Harnett S, editors. 5-Hydroxytryptamine in psychiatry: a spectrum of ideas. Oxford: Oxford University Press, 1991

    Google Scholar 

  107. Friedman MJ. Interrelationships between biological mechanisms and pharmacotherapy of posttraumatic stress disorder. In: Wolf M, Mosnaim A, editors. Posttraumatic stress disorder: etiology, phenomenology and treatment. Washington, DC: American Psychiatric Press Inc., 1990: 204–25

    Google Scholar 

  108. Friedman MJ, Southwick SM. Towards pharmacotherapy for post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 465–81

    Google Scholar 

  109. Sierles FS, Chen J-J, McFarland RE, et al. Post traumatic stress disorder and concurrent psychiatric illness: a preliminary report. Am J Psychiatry 1983; 140: 1177–9

    PubMed  CAS  Google Scholar 

  110. Sierles FS, Chen JJ, Messing ML, et al. Concurrent psychiatrie illness in non-Hispanic outpatients diagnosed as having post traumatic stress disorder. J Nerv Ment Dis 1986; 174: 171–3

    PubMed  CAS  Google Scholar 

  111. Faustman WO, White PA. Diagnostic and psychopharmacological treatment characteristics of 536 inpatients with posttraumatic stress disorder. J Nerv Ment Dis 1989; 177: 154–9

    PubMed  CAS  Google Scholar 

  112. Davidson JRT, Kudler HS, Saunders WB, et al. Symptom and comorbidity patterns in World War II and Vietnam veterans with post traumatic stress disorder. Compr Psychiatry 1990; 31: 162–70

    PubMed  CAS  Google Scholar 

  113. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry 1995; 56: 502–5

    PubMed  CAS  Google Scholar 

  114. Davidson J, Roth S, Newman E. Fluoxetine in post-traumatic stress disorder. J Trauma Stress 1991; 4: 419–23

    Google Scholar 

  115. de Boer M, Op den Velde W, Falger PJR, et al. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom 1992; 57: 158–63

    PubMed  Google Scholar 

  116. Fichtner CG, Arora RC, O’Connor FL, et al. Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sci 1994; 54: PL39–44

    PubMed  CAS  Google Scholar 

  117. Kline NA, Dow BM, Brown SA, et al. Sertraline efficacy in depressed combat veterans with post-traumatic stress disorder [letter]. Am J Psychiatry 1994; 151: 621

    PubMed  CAS  Google Scholar 

  118. March JS. Fluoxetine and fluvoxamine in PTSD [letter]. Am J Psychiatry 1992; 149: 413

    PubMed  CAS  Google Scholar 

  119. Marmar CR, Schoenfeld F, Weiss DS, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 1996; 57 Suppl. 8: 66–72

    PubMed  CAS  Google Scholar 

  120. McDougle CJ, Southwick SM, Charney DS, et al. On open trial of fluoxetine in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 1991; 11: 325–7

    PubMed  CAS  Google Scholar 

  121. Nagy LM, Morgan CA, Southwick SM, et al. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol 1993; 13: 107–13

    PubMed  CAS  Google Scholar 

  122. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress 1996; 9: 865–71

    PubMed  CAS  Google Scholar 

  123. Shay J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat vets with PTSD. J Trauma Stress 1992; 5: 97–101

    Google Scholar 

  124. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517–22

    PubMed  Google Scholar 

  125. Arora RC, Fichtner CG, O’Connor F, et al. Paroxetine binding in the blood platelets of post-traumatic stress disorder patients. Life Sci 1993; 53: 919–28

    PubMed  CAS  Google Scholar 

  126. Fichtner CG, O’Connor FL, Yeoh HC, et al. Hypodensity of platelet serotonin uptake sites in posttraumatic stress disorder: associated clinical features. Life Sci 1995; 57: PL37–44

    PubMed  CAS  Google Scholar 

  127. Prange Jr AJ, Wilson IC, Lynn CW, et al. L-tryptophan in mania: contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974; 30: 56–62

    PubMed  Google Scholar 

  128. Southwick SM, Krystal JH, Morgan CA, et al. Yohimbine and m-chloro-phenyl-piperazine in PTSD. New research abstracts of the American Psychiatrie Association 144th Annual Meeting: 1991 May 11–16; New Orleans, 131–2

    Google Scholar 

  129. Southwick SM, Yehuda R, Morgan III CA. Clinical studies of neurotransmitter alterations in post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 335–49

    Google Scholar 

  130. Zigmond MJ, Finlay JM, Sved AF. Neurochemical studies of central noradrenergic responses to acute and chronic stress: implications for normal and abnormal behavior. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 45–60

    Google Scholar 

  131. Horger BA, Roth RH. Stress and central amino acid systems. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 61–81

    Google Scholar 

  132. Sorg BA, Kalivas PW. Stress and neuronal sensitization. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 83–102

    Google Scholar 

  133. Stout SC, Kilts CD, Nemeroff CB. Neuropeptides and stress: preclinical findings and implications for pathophysiology. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 103–23

    Google Scholar 

  134. van der Kolk BA, Greenberg MS, Orr SP, et al. Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmacol Bull 1989; 25: 417–21

    PubMed  Google Scholar 

  135. Glover H. Emotional numbing: a possible endorphin-mediated phenomenon associated with post-traumatic stress disorders and other allied Psychopathologic states. J Trauma Stress 1992; 5: 643–75

    Google Scholar 

  136. Hoffman L, Watson PB, Wilson G, et al. Low plasma betaendorphin in post-traumatic stress disorder. Aust NZ J Psychiatry 1989; 23: 269–73

    CAS  Google Scholar 

  137. Hoffman L, Watson PB, Wilson G, et al. ‘Low plasma beta-en-dorphin in post-traumatic stress disorder’: correction. Aust NZ J Psychiatry 1989; 23: 442

    Google Scholar 

  138. Hamner MB, Hitri A. Plasma beta-endorphin levels in post-traumatic stress disorder: a preliminary report on response to exercise-induced stress. J Neuropsychiatry Clin Neurosci 1992; 4: 59–63

    PubMed  CAS  Google Scholar 

  139. Wolf ME, Mosnaim AD, Puente J, et al. Plasma methionine-enkephalin in PTSD. Biol Psychiatry 1991; 29: 305–7

    PubMed  CAS  Google Scholar 

  140. Tallman JF, Paul SM, Skolnick P, et al. Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science 1980; 207: 274–81

    PubMed  CAS  Google Scholar 

  141. Nutt DJ, Glue P, Lawson C, et al. Flumazenil provocation of panic attacks. Arch Gen Psychiatry 1990; 47: 917–25

    PubMed  CAS  Google Scholar 

  142. Woods SW, Charney DS, Silver JM, et al. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 1991; 36: 115–27

    PubMed  CAS  Google Scholar 

  143. Randall PK, Bremner JD, Krystal JH, et al. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biol Psychiatry 1995; 38: 319–24

    PubMed  CAS  Google Scholar 

  144. Shalev AY, Rogel-Fuchs Y. Auditory startle reflex in posttraumatic stress disorder patients treated with clonazepam. Isr J Psychiatry Relat Sci 1992; 29: 1–6

    PubMed  CAS  Google Scholar 

  145. Mason JW, Giller EL, Kosten TR, et al. Serum testosterone levels in post-traumatic stress disorder inpatients. J Trauma Stress 1990; 3: 449–57

    Google Scholar 

  146. Mason JW, Wang S, Yehuda R, et al. Some approaches to the study of clinical implications of thyroid alterations in posttraumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 367–79

    Google Scholar 

  147. Rainey JM, Aleem A, Ortiz A, et al. A laboratory procedure for the induction of flashbacks. Am J Psychiatry 1987; 144: 1317–9

    PubMed  Google Scholar 

  148. Jensen CF, Keller TW, Peskind ER, et al. Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Am J Psychiatry 1997; 154: 266–8

    PubMed  CAS  Google Scholar 

  149. Bremner JD, Randall P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152: 973–81

    PubMed  CAS  Google Scholar 

  150. Swayze IIVW, Andreasen NC, Alliger RJ, et al. Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 1992; 31: 221–40

    PubMed  Google Scholar 

  151. Gur RE, Pearlson GD. Neuroimaging in schizophrenia research. Schizophr Bull 1993; 19: 337–53

    PubMed  CAS  Google Scholar 

  152. Myslobodsky MS, Glicksohn J, Singer J, et al. Changes of brain anatomy in patients with posttraumatic stress disorder: a pilot magnetic resonance imaging study. Psychiatry Res 1995; 58: 259–64

    PubMed  CAS  Google Scholar 

  153. Shin LM, Kosslyn SM, McNally RJ, et al. Visual imagery and perception in posttraumatic stress disorder: a positron emission tomographic investigation. Arch Gen Psychiatry 1997; 54: 233–41

    PubMed  CAS  Google Scholar 

  154. True WR, Rice J, Eisen SE, et al. A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. Arch Gen Psychiatry 1993; 50: 257–64

    PubMed  CAS  Google Scholar 

  155. Comings DE, Muhleman D, Gysin R. Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. Biol Psychiatry 1996; 40: 368–72

    PubMed  CAS  Google Scholar 

  156. Frank JB, Kosten TR, Giller Jr EL, et al. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988; 145: 1289–91

    PubMed  CAS  Google Scholar 

  157. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res 1988; 24: 149–55

    PubMed  CAS  Google Scholar 

  158. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47: 259–66

    PubMed  CAS  Google Scholar 

  159. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62

    PubMed  CAS  Google Scholar 

  160. Reist C, Kauffman CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with post-traumatic stress disorder. Am J Psychiatry 1989; 146: 513–6

    PubMed  CAS  Google Scholar 

  161. Braun P, Greenberg D, Dasberg H, et al. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236–8

    PubMed  CAS  Google Scholar 

  162. Blake DD, Weathers FW, Nagy LM, et al. A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behav Ther 1990; 13: 187–8

    Google Scholar 

  163. Katz RJ, Lott MH, Arbus P, et al. Pharmacotherapy of posttraumatic stress disorder with a novel psychotropic. Anxiety 1995; 1: 169–74

    CAS  Google Scholar 

  164. Baker DG, Diamond BI, Gillette G, et al. A double-blind, randomized, placebo-controlled, multicenter study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology 1995; 122: 386–9

    PubMed  CAS  Google Scholar 

  165. Davidson JRT, Nemeroff CB. Pharmacotherapy in posttraumatic stress disorder: historical and clinical considerations and future directions. Psychopharmacol Bull 1989; 25: 422–5

    PubMed  CAS  Google Scholar 

  166. Friedman MJ. Toward rational pharmacotherapy for posttraumatic stress disorder: an interim report. Am J Psychiatry 1988; 145: 281–4

    PubMed  CAS  Google Scholar 

  167. Marshall RD, Klein DF. Pharmacotherapy in the treatment of posttraumatic stress disorder. Psychiatric Ann 1995; 25: 588–97

    Google Scholar 

  168. Silver JM, Sandberg DP, Hales RE. New approaches in the pharmacotherapy of posttraumatic stress disorder. J Clin Psychiatry 1990; 51 Suppl.: 33–8

    Google Scholar 

  169. Southwick SM, Yehuda R, Giller EL, et al. Use of tricyclics and monoamine oxidase inhibitors in the treatment of PTSD: a quantitative review. In: Murburg MM, editor. Catecholamine function in post-traumatic stress disorder: emerging concepts. Washington, DC: American Psychiatric Press Inc., 1994: 293–305

    Google Scholar 

  170. Sutherland SM, Davidson JRT. Pharmacotherapy for post-traumatic stress disorder. Psychiatr Clin North Am 1994; 17: 409–23

    PubMed  CAS  Google Scholar 

  171. van der Kolk BA. Psychopharmacological issues in posttraumatic stress disorder. Hosp Community Psychiatry 1983; 34: 683–91

    PubMed  Google Scholar 

  172. Vargas MA, Davidson J. Post-traumatic stress disorder. Psychiatr Clin North Am 1993; 16: 737–48

    PubMed  CAS  Google Scholar 

  173. Katz L, Fleisher W, Kjernisted K, et al. A review of the psychobiology and pharmacotherapy of posttraumatic stress disorder. Can J Psychiatry 1996; 41: 233–8

    PubMed  CAS  Google Scholar 

  174. Frank JB, Kosten TR, Giller Jr EL, et al. Antidepressants in the treatment of posttraumatic stress disorder. In: Wolf ME, Mosnaim AD, editors. Posttraumatic stress disorder: etiology, phenomenology, and treatment. Washington, DC: American Psychiatric Press Inc., 1990: 170–83

    Google Scholar 

  175. Birkheimer LJ, De Vane CL, Muniz CE. Posttraumatic stress disorder: characteristics and pharmacological response in the veteran population. Compr Psychiatry 1985; 26: 304–10

    Google Scholar 

  176. Davidson JRT, Walker JI, Kilts C. A pilot study of phenelzine in the treatment of post-traumatic stress disorder. Br J Psychiatry 1988; 150: 252–5

    Google Scholar 

  177. Hogben GL, Cornfield RB. Treatment of traumatic war neuroses with phenelzine. Arch Gen Psychiatry 1981; 38: 440–5

    PubMed  CAS  Google Scholar 

  178. Milanes FJ, Mack CN, Dennison J, et al. Phenelzine treatment of post-Vietnam stress syndrome. VA Practitioner 1984; Jun: 40-9

  179. Shen WW, Park S. The use of monoamine oxidase inhibitors in the treatment of traumatic war neurosis. Mil Med 1983; 148: 430–1

    PubMed  CAS  Google Scholar 

  180. Walker JI. Chemotherapy of traumatic war stress. Mil Med 1982; 147: 1029–33

    PubMed  CAS  Google Scholar 

  181. Levenson H, Lanman R, Rankin M. Traumatic war neurosis and phenelzine [letter]. Arch Gen Psychiatry 1982; 39: 1345

    PubMed  CAS  Google Scholar 

  182. Bleich A, Siegel B, Garb R, et al. Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment. Br J Psychiatry 1986; 149: 365–9

    PubMed  CAS  Google Scholar 

  183. Lerer B, Bleich A, Kotler M, et al. Posttraumatic stress disorder in Israeli combat veterans: effects of phenelzine treatment. Arch Gen Psychiatry 1987; 44: 976–81

    PubMed  CAS  Google Scholar 

  184. Blake DJ. Treatment of acute posttraumatic stress disorder with tricyclic antidepressants. South Med J 1986; 79: 201–4

    PubMed  CAS  Google Scholar 

  185. Burstein A. Treatment of flashbacks by imipramine. Psychosomatics 1984; 25: 683–7

    Google Scholar 

  186. Marshall JR. The treatment of night-terrors associated with posttraumatic stress syndrome. Am J Psychiatry 1975; 132: 293–5

    PubMed  CAS  Google Scholar 

  187. Falcon S, Ryan C, Chamberlain K, et al. Tricyclics: possible treatment for posttraumatic stress disorder. J Clin Psychiatry 1985; 46: 385–8

    PubMed  CAS  Google Scholar 

  188. White NS. Post-traumatic stress disorder [letter]. Hosp Community Psychiatry 1983; 34: 1061–2

    PubMed  CAS  Google Scholar 

  189. Chen C-J. The obsessive quality and clomipramine treatment in PTSD. Am J Psychiatry 1991; 148: 1087–8

    PubMed  CAS  Google Scholar 

  190. Liebowitz NR, El-Mallakh RS. Trazodone for the treatment of anxiety symptoms in substance abusers. J Clin Psycho-pharmacol 1989; 9: 449–51

    CAS  Google Scholar 

  191. Hertzberg MA, Feldman ME, Beckham JC, et al. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol 1996; 16: 294–8

    PubMed  CAS  Google Scholar 

  192. Southwick SM, Yehuda R, Giller Jr EL, et al. Use of tricyclics and monamine oxidase inhibitors in the treatment of PTSD: a quantitative review. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatrie Press Inc., 1994: 293–305

    Google Scholar 

  193. Horowitz M, Wilner N, Alvarez N. Impact of events scale: a measure of subjective stress. Psychosom Med 1979; 41: 209–18

    PubMed  CAS  Google Scholar 

  194. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71

    PubMed  CAS  Google Scholar 

  195. Spielberger CD. State-trait anxiety inventory. Palo Alto (CA): Consulting Psychologists Press, 1985

    Google Scholar 

  196. Guy W. ECDEU assessment manual for psychopharmacology. Rev. Rockville (MD): National Institute of Mental Health, 1976

    Google Scholar 

  197. Falsetti SA, Resnick HS, Resick PA, et al. The modified PTSD symptom scale: a brief self-report measure of posttraumatic stress disorder. Behavior Therapist 1993; 16: 161–2

    Google Scholar 

  198. Davidson J, Weisler R. Nefazodone in post traumatic stress disorder [abstract]. Proceedings of the American College of Neuropsychopharmacology: 1996 Oct; Puerto Rico, 177

  199. Wells BG, Chu C-C, Johnson R, et al. Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy 1991; 11: 340–3

    PubMed  CAS  Google Scholar 

  200. Fichtner CG, Crayton JW. Buspirone in combat-related posttraumatic stress disorder. J Clin Psychopharmacol 1994; 14: 79–81

    PubMed  CAS  Google Scholar 

  201. LaPorta LD, Ware MR. Buspirone in the treatment of posttraumatic stress disorder. J Clin Psychopharmacol 1992; 12: 133–4

    PubMed  CAS  Google Scholar 

  202. Schwartz LS. A biopsychosocial treatment approach to posttraumatic stress disorder. J Trauma Stress 1990; 3: 221–38

    Google Scholar 

  203. Simpson MA. Buspirone, benzodiazepines, and post-traumatic stress disorder. J Trauma Stress 1991; 4: 305–8

    Google Scholar 

  204. Harsch HH. Cyproheptadine for recurrent nightmares. Am J Psychiatry 1986; 143: 1491–2

    PubMed  CAS  Google Scholar 

  205. Brophy MH. Cyproheptadine for combat nightmares in posttraumatic stress disorder and dream anxiety disorder. Mil Med 1991; 156: 100–1

    PubMed  CAS  Google Scholar 

  206. Kolb LC, Burris BC, Griffiths S. Propranolol and Clonidine in the treatment of post traumatic disorders of war. In: van der Kolk BA, editor. Post traumatic stress disorder: psychological and biological sequelae. Washington, DC: American Psychiatric Press Inc., 1984: 97–107

    Google Scholar 

  207. Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 1989; 177: 546–50

    PubMed  CAS  Google Scholar 

  208. Perry BD. Neurobiological sequelae of childhood trauma: PTSD in children. In: Murburg MM, editor. Catecholamine function in posttraumatic stress disorder. Washington, DC: American Psychiatrie Press Inc., 1994: 233–55

    Google Scholar 

  209. Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type. Am J Dis Child 1988; 142: 1244–7

    PubMed  CAS  Google Scholar 

  210. Braun BG. Unusual medication regimen in the treatment of dissociative disorder patients: part I: noradrenergic agents. Dissociation 1990; 3: 144–50

    Google Scholar 

  211. Hollister LE, Muller-Oerlinghausen B, Rickeis K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13 Suppl. 1: 1–169S

    Google Scholar 

  212. Feldman TB. Alprazolam in the treatment of posttraumatic stress disorder. J Clin Psychiatry 1987; 48: 216–7

    Google Scholar 

  213. Giller Jr EL, Kosten RT, Yehuda R, et al. Psychoendocrinology and pharmacotherapy of PTSD. Clin Neuropharmacol 1990; 13 Suppl. 2: 329–30

    Google Scholar 

  214. Dunner FJ, Edwards WP, Copeland PC. Clinical efficacy of alprazolam in PTSD patients. New research abstracts of the American Psychiatrie Association 138th Annual Meeting 1985

    Google Scholar 

  215. Loewenstein RJ, Hornstein N, Farber B. Open trial of clonazepam in the treatment of posttraumatic stress symptoms in MPD. Dissociation 1988; 1: 3–12

    Google Scholar 

  216. Risse SC, Whitters A, Burke J, et al. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry 1990; 51: 206–9

    PubMed  CAS  Google Scholar 

  217. Patterson JF. Withdrawal from alprazolam dependency using clonazepam: clinical observations. J Clin Psychiatry 1990; 51(5 Suppl.): 47–9

    PubMed  Google Scholar 

  218. Post RM, Kopanda RT. Cocaine, kindling, and psychosis. Am J Psychiatry 1976; 133: 627–34

    PubMed  CAS  Google Scholar 

  219. Post RM. Clinical implications of a cocaine-kindling model of psychosis. Clin Neuropharmacol 1977; 2: 25–42

    Google Scholar 

  220. Post RM, Contel NR. Human and animal studies of cocaine: implications for development of behavioral pathology. In: Creese I, editor. Stimulants: neurochemical, behavioral, and clinical perspective. New York: Raven Press, 1983: 169–203

    Google Scholar 

  221. Post RM, Weiss SRB, Smith MA. Sensitization and kindling: implications for the evolving neural substrates of post-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, editors. Neurobiological and clinical consequences of stress: from normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott-Raven, 1995: 203–24

    Google Scholar 

  222. Lipper S. Carbamazepine in the treatment of posttraumatic stress disorder: implications for the kindling hypothesis. In: Wolf ME, Mosnaim AD, editors. Posttraumatic stress disorder: etiology, phenomenology, and treatment. Washington, DC: American Psychiatric Press Inc., 1990: 184–203

    Google Scholar 

  223. Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27: 849–54

    PubMed  CAS  Google Scholar 

  224. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23: 642–4

    PubMed  CAS  Google Scholar 

  225. Looff D, Grimley P, Kuller F, et al. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995; 34: 703–4

    PubMed  CAS  Google Scholar 

  226. Bennett TL, Curiel MR Complex partial seizures presenting as a psychiatric illness. Int J Clin Neuropsych 1988; 10: 41–4

    Google Scholar 

  227. Brodsky L, Doerman AL, Palmar LS, et al. Post-traumatic stress disorder: a tri-modal approach. Psychiatr J Univ Ott 1987; 12: 41–6

    PubMed  CAS  Google Scholar 

  228. Stewart JR, Bartucci RJ. Post-traumatic stress disorder and partial complex seizures. Am J Psychiatry 1986; 143: 113–4

    PubMed  CAS  Google Scholar 

  229. Szymanski HV, Herman V, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991; 148: 1086–7

    PubMed  CAS  Google Scholar 

  230. Brodsky L, Doerman AL, Palmar LS, et al. Post-traumatic stress disorder: an eclectic approach. Int J Psychosom 1990; 37: 89–95

    PubMed  CAS  Google Scholar 

  231. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52: 361–4

    PubMed  CAS  Google Scholar 

  232. Kitchner I, Greenstein R. Low dose lithium carbonate in the treatment of posttraumatic stress disorder: brief communication. Mil Med 1985; 150: 378–81

    PubMed  CAS  Google Scholar 

  233. van der Kolk BA. Psychopharmacological issues in posttraumatic stress disorder. Hosp Community Psychiatry 1983; 34: 683–91

    PubMed  Google Scholar 

  234. Irwin M, Van Putten T, Guze B, et al. Pharmacologie treatment of veterans with posttraumatic stress disorder and concomitant affective disorder. Ann Clin Psychiatry 1989; 1: 127–30

    Google Scholar 

  235. Lucking RG. Bipolar disorder in post-traumatic stress disorder: a difficult diagnosis: case reports. Mil Med 1986; 151: 282–4

    PubMed  CAS  Google Scholar 

  236. Macleod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996; 16: 190–1

    PubMed  CAS  Google Scholar 

  237. Meuser KT, Butler RW. Auditory hallucinations in combat-related chronic post-traumatic stress disorder. Am J Psychiatry 1987; 144: 299–302

    Google Scholar 

  238. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci 1993; 30: 255–63

    PubMed  CAS  Google Scholar 

  239. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone [letter]. Am J Psychiatry 1993; 150: 1430

    PubMed  CAS  Google Scholar 

  240. Braun BG. The use of naltrexone in the treatment of dissociative disorder patients [abstract]. Braun BG, Carlson EB, editors. Proceedings of the 7th International Conference on Multiple Personality/Dissociative States: 1990 Nov 9–11; Chicago, 20

    Google Scholar 

  241. Davidson JRT, Kudler HS, Smith RD. Assessment and pharmacotherapy of posttraumatic stress disorder. In: Giller Jr EL, editor. Biological assessment and treatment of posttraumatic stress disorder. Washington DC: American Psychiatrie Press Inc., 1990: 203–33

    Google Scholar 

  242. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5

    PubMed  CAS  Google Scholar 

  243. Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry 1992; 53: 83–5

    PubMed  CAS  Google Scholar 

  244. Kudler HS, Davidson JRT, Stein R, et al. Measuring results of treatment of PTSD. Am J Psychiatry 1989; 146: 1645–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioural Sciences, and Illinois Department of Human Services, Finch University of Health Sciences/The Chicago Medical School, Chicago, Illinois, USA

    Christopher G. Fichtner

  2. Pharmacy Service, Department of Veterans Affairs, Edward Hines Jr Hospital, Hines, Illinois, USA

    Barbara E. Poddig

  3. Department of Psychiatry, Loyola University Stritch School of Medicine, Maywood, Illinois, USA

    Robert A. de Vito

Authors
  1. Christopher G. Fichtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara E. Poddig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. de Vito
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fichtner, C.G., Poddig, B.E. & de Vito, R.A. Post-Traumatic Stress Disorder. CNS Drugs 8, 293–322 (1997). https://doi.org/10.2165/00023210-199708040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199708040-00004

Keywords

Search

Navigation